Serum levels of platelet endothelial cell adhesion molecule-1 (PECAM-1) and soluble vascular endothelial growth factor receptor (sVEGFR)-1 and -2 in HIV associated preeclampsia

References

• Republic of South Africa. Department of Health. Saving Mothers 2011–2013: Sixth report on the confidential enquiries into maternal deaths in South Africa. National Department of Health; 2011–2013.
   Google Scholar
• Pretoria. Department of Health. The 2012 national antenatal sentinel HIV and herpes simplex type-2 prevalence survey in South Africa. National Department of Health; 2012.
   Google Scholar
• Kalumba VMS, Moodley J, Naidoo TD. Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospect case-study. CVJ Africa 2013;24:24–27.
   Web of Science ®Google Scholar
• Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic factors and anti-angiogenic factors in HIV-infected women with pre-eclampsia. CVJ Africa 2013a;24:174–179.
   Web of Science ®Google Scholar
• Imran M, Manzoor S, Saalim M, et al. HIV-1 and hijacking of the host immune system: the current scenario. APMIS 2016;1–15.
   Google Scholar
• Boyajian T, Shah PS, Murphy KE. Risk of pre-eclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can 2012;34(2):136–141.
   PubMedGoogle Scholar
• Frank KA. HIV and pre-eclampsia: is there a connection? [Unpublished thesis] University of the Witwatersrand; 2006.
   Google Scholar
• Cerdeira AS, Karumanchi SA. Angiogenic factors in preeclampsia and related disorders. Perspect Med 2012;2:1–18.
   Google Scholar
• Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin N Am 2010 37:239–253.
   PubMed Web of Science ®Google Scholar
• Uzan J, Carbonnel M, Piconne O, et al. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag 2011;7:467–474.
   PubMedGoogle Scholar
• Govender N, Naicker T, Rajakumar A, Moodley J. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2013b;170:100–105.
   PubMed Web of Science ®Google Scholar
• Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiol 2009;24:147–158.
   PubMed Web of Science ®Google Scholar
• Lorquet S, Berndt S, Balcher S, et al. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEBJ 2010;24:3782–3795.
   PubMed Web of Science ®Google Scholar
• Powe CE, Levine RJ, Karumanchi A. Pre-eclampsia, a disease of the maternal endothelium. The role of angiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–2869.
   Google Scholar
• Thadhani R, Kisner T, Hagman H, et al. Pilot study of extracorporeal removal of soluble Fms-like tyrosine kinase 1 in pre-eclampsia. Ciculation 2011;124:940–950.
   PubMed Web of Science ®Google Scholar
• Ho VC, Duan LJ, Cronin C, et al. Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1–deficient mice. Circulation 2012;126:741–752.
   PubMed Web of Science ®Google Scholar
• Munaut C, Lorquet S, Pequeux C, et al. Differential expression of VEGFR-2 and its soluble form in pre-eclampsia. Plos One 2012;7(3):1–8.
   Web of Science ®Google Scholar
• Luizon MR, Sandrim VC, Palei ACT, et al. Epistasis among eNOS, MMP-9 and VEGF maternal genotypes in hypertensive disorders of pregnancy. Hypertens Res 2012;35:917–921.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimbery A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–372.
   PubMed Web of Science ®Google Scholar
• Yasemin A, Erol G, Nazli M, Yildiz SE. Significance of platelet endothelial cell adhesion molecule – 1 (PECAM – 1) and intercellular adhesion molecule – 1 (ICAM – 1) expression in preeclamptic placentae. Endocrine 2012;42:125–131.
   PubMed Web of Science ®Google Scholar
• Valenzuela FJ, Perez-Sepulveda A, Torres MJ, et al. Pathogenesis of pre-eclampsia: the genetic component. J Pregnancy 2012;1–8.
   Google Scholar
• Lapire O, Shennan A, Stepan H. The pre-eclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010;151:122–129.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Tarca A, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of pre-eclampsia. Am J Obstet Gynecol 2010;202(6):1–22.
   PubMed Web of Science ®Google Scholar
• Koga K, Osunga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Mteab 2003;88(5):2348–2351.
   PubMed Web of Science ®Google Scholar
• Molvarec A, Szarka A, Walentin S, et al. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010;33(9):892–8.
   PubMed Web of Science ®Google Scholar
• Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochem Soc Trans 2011;39(6):1576–1582.
   PubMed Web of Science ®Google Scholar
• Crispi F, Llurba E, Dominguez C, et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303–309.
   PubMed Web of Science ®Google Scholar
• Tripathi R, Rath G, Ralhan R, et al. Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia. Yonsei Med J 2009;50(5):656–666.
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer IA, Boswell F, et al. Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Placenta 1995;16:579–587.
   PubMed Web of Science ®Google Scholar
• Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360 (9340):1152–1154.
   PubMed Web of Science ®Google Scholar
• Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006;20:59–66.
   PubMed Web of Science ®Google Scholar
• Powis KM, McElrath TF, Hughes MD, et al. High Viral Load and Elevated Angiogenic Markers Associated with Increased Risk of Preeclampsia among Women Initiating Highly Active Antiretroviral Therapy (HAART) in Pregnancy in the Mma Bana Study, Botswana. J Acquir Immune Defic Syndr 2013;62(5):517–524.
   PubMed Web of Science ®Google Scholar